Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression. The most notable side effect of this therapy is drug-induced liver injury; howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Espinosa, Diana, Broseta, José Jesús, Bastida, Carla, Álvarez-Mora, María Isabel, Nicolau, Carlos, Alvarez, Cristina, Agraz-Pamplona, Irene, Sánchez-Baya, Maya, Furlano, Mónica, Ruiz, César, Quintana, Luis F., Piñeiro, Gastón J., Poch, Esteban, Torra-Balcells, Roser, Blasco, Miquel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Clinical Practice: Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137304/
https://www.ncbi.nlm.nih.gov/pubmed/36088902
http://dx.doi.org/10.1159/000526368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137304/
https://www.ncbi.nlm.nih.gov/pubmed/36088902
http://dx.doi.org/10.1159/000526368

Ejemplares similares